KA2507 - 10mM in DMSO , CAS No.1636894-46-6

CAS: 1636894-46-6 Cat. No.: K654456 Molecular Weight: 322.32 PubChem CID: 117703516
AVAILABLE TO ORDER
GRADE & PURITY 10mM in DMSO
Storage
Protected from light,Store at -80°C
Shipped In
Dry ice packs + Cold packs
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
1ml
K654456-1ml
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$29.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Protected from light,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC 50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models

In Vitro

KA2507 did not inhibit the in vitro proliferation of mouse or human cancer cells at concentrations that are selective for HDAC6 inhibition. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model . KA2507 also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models . Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I . KA2507 exhibits poor oral bioavailability (mice 15%) and C max (mice 300 ng/mL) following oral administration (mice 200 mg/kg) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6 mice, B16-F10 melanoma model Dosage: 100 mg/kg, 200 mg/kg, 200 mg/kg Administration: Oral gavage, daily, for 20 days Result: Demonstrated antitumor efficacy. Animal Model: Male C57BL/6 mice Dosage: 200 mg/kg (Pharmacokinetic Analysis) Administration: Oral administration Result: Oral bioavailability (15%), C max (300 ng/mL).

IC50& Target:HDAC6 2.5 nM (IC 50 ) HDAC8 621 (IC 50 )

Specifications

Specifications & Purity
10mM in DMSO
Biochemical and Physiological Mechanisms
KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC 50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models.
Storage
Protected from light, Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
INHIBITOR
Names and Identifiers
Isomeric SMILES C1=CC(=CC=C1CN(C2=NC=CN=C2)C3=NC=CN=C3)C(=O)NO
Alternate CAS 1636894-46-6
PubChem CID 117703516
Molecular Weight 322.32

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.